Extended Data Table 1 α6 integrin expression is associated with CNS relapse independently of other known risk factors for CNS disease recurrence

From: Leukaemia hijacks a neural mechanism to invade the central nervous system

  1. Summary of clinical data for patients with ALL. Statistical testing was performed to determine potential associations between α6 integrin expression and known risk factors for CNS disease relapse. Fisher’s exact test, n = 19 patients without CNS relapse, n = 8 patients with CNS relapse, α6 integrin immunohistochemistry score (0–0.5+, 1+ or 2+–3+) versus age at diagnosis (paediatric <15 years or adult): P = 0.8416; immunohistochemistry score versus white blood cell count at diagnosis (low <30 (109 per l) or high >30 (109 per l), P = 0.8119; immunohistochemistry score versus Philadelphia chromosome status: P = 0.4676; α6 integrin immunohistochemistry score versus CD56 status: P = 0.2332). BCR, breakpoint cluster region; BCR/ABL1, breakpoint cluster region/Abelson murine leukaemia viral oncogene homologue 1; BM, bone marrow; IgH, immunoglobulin heavy locus; IHC, immunohistochemistry; MLL, mixed-lineage leukaemia; Ph, Philadelphia chromosome; RUNX1, Runt-related transcription factor 1; WBC, white blood cells.
Back to article page